Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 2026 Muscular Dystrophy Association (MDA) Clinical and ...

Edgewise Therapeutics overview Edgewise Therapeutics (EWTX) has drawn investor attention after recent share price moves, with the stock showing mixed short term performance alongside meaningful gains ...

Edgewise Therapeutics Inc., a Boulder-based biopharmaceutical company that develops therapies for muscle disease, spent more on research and development and administration during the fourth quarter of ...

Edgewise Therapeutics plans to meet with regulators in the U.S. and Europe to discuss how much clinical trial evidence it needs to seek expedited approval of its experimental drug for a form of ...

That professional was Guggenheim's Debjit Chattopadhyay, who initiated his Edgewise Therapeutics coverage with a buy recommendation, and price target of $41 per share. That's well more than double the ...

BOULDER, Colo., Nov. 10, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and ...

Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac ...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the U.S. Food & Drug Administration (FDA) has ...

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) shares are trading higher Friday after the company announced the pricing of its $240 million underwritten offering of 21,818,182 shares at $11 per share.

Edgewise's Phase 2 trial for sevasemten in Becker muscular dystrophy showed a 28% average CK reduction vs. placebo (p=0.02). Functional measures, including NSAA and timed walking tests, showed ...

- Trial to inform the disease progression of individuals with BMD - “The severity and progression of symptoms common in BMD, like progressive muscle weakness, vary from person to person and have posed ...